Alkermes (ALKS) EBIT Growth (1y) (2011 - 2026)
Alkermes (ALKS) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | -150.77% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | -10.00% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | -0.93% |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | -9.25% |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | -97.30% |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 4.05% |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 12.73% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | -80.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -80.26% |
| Mar 31, 2026 | -450.06% |
| Dec 31, 2025 | -64.29% |
| Sep 30, 2025 | -14.96% |
| Jun 30, 2025 | -15.38% |
| Mar 31, 2025 | -68.15% |
| Dec 31, 2024 | 197.79% |
| Sep 30, 2024 | 17.45% |
| Jun 30, 2024 | -60.93% |
| Mar 31, 2024 | 494.72% |
| Dec 31, 2023 | -52.74% |
| Sep 30, 2023 | 247.09% |
| Jun 30, 2023 | 916.29% |
| Mar 31, 2023 | 58.73% |
| Dec 31, 2022 | -10.68% |
| Sep 30, 2022 | -208.46% |
| Jun 30, 2022 | -879.39% |
| Mar 31, 2022 | -61.79% |
| Dec 31, 2021 | 521.15% |
| Sep 30, 2021 | -84.30% |